Pharmaceutical formulations
AssigneeNovo Nordisk A/S
InventorsTommy Sander, Christian Poulsen, Rosa Rebecca Erritzoee Hansen
Life of this patent
Estimating the term…
Abstract
Disclosed herein are an aqueous pharmaceutical formulation comprising cagrilintide and an aqueous formulation comprising semaglutide. The compositions of these two pharmaceutical formulations allow for their presentation in, and administration using, the dual-chamber medical device disclosed herein. Individuals with diseases, such as diabetes and/or obesity and/or related co-morbidities, may benefit from the co-administration of semaglutide and cagrilintide, and/or of the two liquid pharmaceutical formulations disclosed herein, using the medical device disclosed herein.
Claims30
A medical device comprising a first chamber and a second chamber, wherein the first chamber comprises an aqueous semaglutide formulation and the second chamber comprises an aqueous cagrilintide formulation,
- wherein the aqueous semaglutide formulation comprises:
- semaglutide;
- phosphate, in a concentration of more than 15 mM and less than or equal to 45 mM;
- 90-99% w/w water;
- and
- a pH of 7.0-8.0, and
- wherein the cagrilintide formulation comprises:
- cagrilintide;
- a buffer which is:
- glutamic acid/glutamate, in a concentration of about 2-10 mM;
- or lactic acid/lactate, in a concentration of about 2-35 mM;
- or acetic acid/acetate, in a concentration of about 2-10 mM;
- 90-99% w/w water;
- and
- a pH of 3.5-4.5.
A medical device comprising a first chamber and a second chamber, wherein the first chamber comprises an aqueous semaglutide formulation and the second chamber comprises an aqueous cagrilintide formulation,
- wherein the aqueous semaglutide formulation comprises:
- semaglutide;
- phosphate, in a concentration of about 30 mM;
- histidine, in a concentration of about 10 mM;
- sodium chloride, in a concentration of about 6.4 mg/ml;
- and
- has a pH of 7.4, and
- wherein the aqueous cagrilintide formulation comprises:
- cagrilintide;
- a glutamic acid/glutamate buffer, in a concentration of about 5 mM;
- glycerol in a concentration of about 24 mg/ml;
- and
- a pH of 4.0.
Dependencies are inferred from the claim text.